|
No images? Click here A new way to treat depression, anxiety and chronic neuropathic pain Newsletter No 27 (16 September 2024) Depression, neuroinflammation & ketamine...
Ketamine's utility as a potent anti-inflammatory agent is well known. In a previous newsletter we linked to a systematic review exploring this. Co-authored by the 'father' of ketamine for MDD, Carlos Zarate, a new review article published in Molecular Psychiatry examines ketamine's immunoregulatory mechanism and focuses on the role of the complement system in mediating these effects. Crucially, the complement system plays a fundamental role in synaptic plasticity and synaptic pruning. Studies have shown increased C3 expression in the prefrontal cortex of depressed and suicidal patients. 10,000 safe ketamine infusions... "This achievement underscores our commitment to patient safety. Congratulations to all our medical and nursing staff around the country." (Dr Alan Howard) Since humble beginnings in the Natal Midlands in 2019, KetaMIND clinics around the country have now collectively administered over 10,000 safe ketamine infusions. KetaMIND clinics maintain patient
safety standards through a robust internal audit system. Updated anaesthesia / sedation and life-support skills, as well as comprehensive patient monitoring are crucial elements of our commitment to patient safety.
KetaMIND has opened a new clinic in Bryanston... Our new clinic opened its doors on 2nd September at 18 Ealing Crescent, Bryanston, Gauteng. Visit our website for contact details. Following the success of our Bedfordview clinic, which opened in 2020, we are delighted to announce that we have expanded our services in Gauteng to Bryanston where we opened our 7th clinic on 2nd September. We wish Dr Greg Stewart and his team everything of the best for this new and exciting initiative.
Case Report: Ketamine infusions in a patient with bipolar disorder and autism...
The probability of shared genetics between bipolar disorder (BD) and autism spectrum disorders (ASD) is well documented. Published in Frontiers in Psychiatry in Feb '24, the authors of this case study involving comorbid BD and ASD crucially conclude that ketamine infusion therapy (KIT) is not contraindicated in ASD. The outcome of the treatment for this patient was encouraging. KetaMIND Paarl has been open for a year!
From left to right: Kathryn Mann (Managing Director), Dr Alan Howard (National Medical Director and KetaMIND founder), Dr Talitha Harvey (Clinical Director). Congratulations to Kathryn Mann and her team for reaching this milestone!
KetaMIND clinics currently offer outpatient ketamine infusions at the following locations:BEDFORDVIEW / BRYANSTON (GP) CONSTANTIA (WC) UMHLANGA (KZN) PIETERMARITZBURG (KZN) HILLCREST (KZN) PAARL (WC)
|